	US 12,268,688 B2
	Compositions and methods of use for modified release minoxidil
Reid Waldman, West Hartford, CT (US)
Assigned to Veradermics Incorporated, West Hartford, CT (US)
Filed by Veradermics Incorporated, West Hartford, CT (US)
Filed on Feb. 9, 2024, as Appl. No. 18/437,724.
Application 18/437,724 is a continuation of application No. PCT/US2023/035920, filed on Oct. 25, 2023.
Claims priority of provisional application 63/433,203, filed on Dec. 16, 2022.
Claims priority of provisional application 63/419,155, filed on Oct. 25, 2022.
Prior Publication US 2024/0252495 A1, Aug. 1, 2024
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61P 17/14 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/28 (2013.01); A61P 17/14 (2018.01)]

29 Claims

1. A method of treating hair loss, comprising orally administering to a subject in need thereof a modified release pharmaceutical formulation comprising from about 3.5 mg to about 20 mg of minoxidil or a pharmaceutically acceptable salt thereof; wherein wherein the modified release pharmaceutical formulation provides:

a blood level of the minoxidil or a pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml;

a Cmax of about 0.25 ng/ml to about 20 ng/ml; and

a Tmax of about 30 to about 360 minutes.